Guangshengtang announced that the GST-Peak-Triple half-year full oral anti-hepatitis B phase II clinical trial conducted by Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the holding subsidiary of the company, has recently completed the enrollment of all 176 subjects. The program consists of GST-HG141 and GST-HG131 combined nucleoside drugs. Both drugs have been included in the list of breakthrough treatment varieties. The joint plan has been selected for innovative drug clinical trial review and approval pilots and major national science and technology projects. The completion of enrollment this time does not mean that follow-up research and approval results will be determined; there is a risk of uncertainty in the development of innovative drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.